New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export PBM’s income statement to Excel — free account
Psyence Biomedical Ltd.
PBM
2.97
0.11
+3.85%
After hours trading: 3.01, up 1.35%, last trade Fri 4:09pm Eastern.
Follow PBM
Alert me
Ratios over time FY23 to FY26
Returns on capital
ROIC was −41.2% in FY26, against a low of −415.6% in FY25. ROE, at −58.6%, is far above it because equity is small against the capital the business uses.
ROEROIC
| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| ROE | −54.7% | 149.5% | −47.6% | −58.6% |
| ROIC | 0.0% | 0.0% | −415.6% | −41.2% |
Debt
Net debt is 1.20× a year’s EBITDA. Debt is 0.00× equity.
Debt / equityNet debt / EBITDA
| FY20 | FY21 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|
| Debt / equity | 0.0× | 0.0× | 0.0× | 0.0× | 0.0× | 0.0× |
| Net debt / EBITDA | 1.9× | 0.1× | 0.3× | 0.3× | 1.7× | 1.2× |
| Dec '17 | Jan '21 | Jan '22 | Dec '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
— | 14.17 | 0.08 | 0.09 | 0.09 | 11.04 | 14.62 |
Net Debt/EBITDA |
— | 1.94 | 0.10 | 0.28 | 0.28 | 1.69 | 1.20 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | (0.10) | (0.06) | — | 0.06 | (3.69) | 1.17 |
Capex/Depreciation |
— | — | — | — | (28.50) | (2.30) | (0.04) |
Interest Coverage |
— | (278.58) | (0.73) | (52.03) | (52.02) | (393.87) | (656.58) |
| — | — | 3.33% | (54.66%) | 149.52% | (47.61%) | (58.62%) | |
| — | 6.42% | 3.11% | (39.34%) | (4,518.56%) | 23.95% | (55.75%) | |
ROIC |
— | — | — | 0.00% | 0.00% | (415.57%) | (41.24%) |
Return on Tangible Assets |
— | 909.94% | (61.34%) | 466.25% | 466.25% | 16.93% | (81.67%) |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (0.03) | (0.02) | — | (1,735.94) | (121.17) | (14.74) |
Cash per Share |
— | 0.02 | 0.00 | 0.09 | 448.71 | 199.71 | 13.57 |
Shareholders Equity per Share |
— | 7.24 | 7.49 | (1.32) | (6,454.41) | 217.54 | 30.68 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 7.24 | 7.49 | (1.32) | (6,454.41) | 217.54 | 30.68 |
Free Cash Flow |
— | (0.84) | (0.52) | — | (2.95) | (3.74) | (8.14) |
Working Capital |
— | 0.90 | (13.07) | (10.98) | (10.98) | 5.97 | 8.49 |
Capital Expenditures |
— | — | — | — | (0.01) | (0.01) | 0.00 |
Net Current Asset Value |
— | (18.61) | (13.07) | (10.98) | (10.98) | 5.97 | 8.49 |
| Other line items | |||||||
Quick Ratio |
— | 9.44 | 0.07 | 0.07 | 0.07 | 10.61 | 12.60 |
Depreciation/Fixed assets |
— | — | — | — | 0.04 | 0.39 | 0.87 |
Cash ROIC |
— | (0.35%) | (0.21%) | — | 28.90% | (29.04%) | (33.32%) |
Operating CF per Share |
— | (0.03) | (0.02) | — | (1,732.59) | (120.85) | (14.74) |
Capex per Share |
— | 0.00 | 0.00 | — | (3.35) | (0.32) | 0.00 |
Average Receivables |
— | — | — | 0.44 | 0.04 | 0.09 | 0.25 |
Average Payables |
— | — | — | — | — | 0.57 | 0.40 |
Average Assets |
— | 128.11 | 257.58 | 130.03 | 1.13 | 4.22 | 12.44 |
Average Common Equity |
— | — | 240.65 | 93.60 | (34.22) | (2.13) | 11.83 |
Columns are period end dates